Treatment of Gray Platelet Syndrome

• References

• 1 Pfueller SL, Howard MA, White JG, Menon C, Berry EW. Shortening of the bleeding time by l-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in gray platelet syndrome. Thromb Haemostas 1987; 58: 1060-1063
• 2 Köhler M, Hellstem P, Morgenstern E, Mueller-Eckhardt C, Berberich R, Meiser RJ, Scheffler P, Wenzel E. Gray platelet syndrome: Selective alpha granule deficiency and thrombocytopenia due to increased platelet turnover. Blut 1985; 50: 331-340
• 3 Mannucci PM, Vicente V, Vianello L, Cattaneo M, Alberca I, Coccato MP, Faioni E, Mari D. Controlled trial of desmopressin in liver cirrhosis and other conditions with a prolonged bleeding time. Blood 1986; 67: 1148-1153
• 4 Racugglia G. Gray platelet syndrome. A variety of qualitative platelet disorder Am J Med 1971; 51: 818-828
• 5 Gerrard JM, Phillips DR, Rao GH R, Plow EF, Walz DA, Ross R, Harker LA, White JG. Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha-granules J Clin Invest 1980; 66: 102-109
• 6 White JG, Gerrard JM. Ultrastructural features of of abnormal blood platelets. A review Am J Pathol 1976; 83: 590-614